Revenue declined year-over-year, but gross profit and adjusted EBITDA margins improved due to operational efficiencies and cost savings. Healthcare and Industry segments grew, offsetting declines in Beauty and Drug Delivery, while restructuring costs impacted EBIT. Guidance remains for stable margins and modest growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.